Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.17.

EBIT: As of FY2026 Q1, the actual value is USD -13.2 M.

Biomea Fusion, Inc. operates as one reportable segment and has not generated any revenue from product sales since its inception, expecting continued and increasing operating losses as clinical development advances .

Operational Metrics (Three Months Ended March 31)

• Net Loss: Biomea Fusion, Inc. reported a net loss of - $12,415 thousand for 2026, a significant decrease from the - $29,262 thousand net loss in 2025 .
• Total Operating Expenses: Total operating expenses decreased to $12,774 thousand in 2026 from $29,712 thousand in 2025 .
  • Research and Development (R&D) Expenses: R&D expenses decreased by $13,777 thousand, from $22,897 thousand in 2025 to $9,120 thousand in 2026 . This reduction was primarily due to a $7,600 thousand decrease in external costs, including a $3,800 thousand decrease in clinical activities and a $1,900 thousand decrease in preclinical and exploratory programs, alongside a $4,500 thousand decrease in personnel-related expenses and a $1,700 thousand decrease in facilities and other allocated expenses . Clinical research organization expenses for COVALENT-101, COVALENT-102, COVALENT-111, and COVALENT-112 were $0 in 2026, compared to $1,001 thousand, $614 thousand, $2,242 thousand, and $502 thousand respectively in 2025 . Conversely, COVALENT-211 and COVALENT-212 incurred $743 thousand and $562 thousand respectively in 2026, up from $0 in 2025, and GLP-131 expenses rose to $1,425 thousand in 2026 from $0 in 2025 .
  • General and Administrative (G&A) Expenses: G&A expenses decreased by $3,161 thousand, from $6,815 thousand in 2025 to $3,654 thousand in 2026 . This was mainly driven by a $1,900 thousand decrease in personnel-related expenses and a $1,100 thousand decrease in corporate-related expenses .
• Loss from Operations: Loss from operations decreased to - $12,774 thousand in 2026 from - $29,712 thousand in 2025 .
• Change in fair value of common warrant liability: This resulted in a - $581 thousand impact in 2026, compared to $0 in 2025 .
• Gain on sale of property and equipment: Biomea Fusion, Inc. recognized a gain of $510 thousand in 2026, compared to $0 in 2025, primarily from the sale of laboratory equipment .
• Interest and other income, net: This decreased slightly from $450 thousand in 2025 to $430 thousand in 2026 .

Cash Flow (Three Months Ended March 31)

• Net cash used in operating activities: - $11,669 thousand in 2026, compared to - $25,667 thousand in 2025 .
• Net cash provided by investing activities: $550 thousand in 2026, compared to $0 in 2025, primarily from the sale of property and equipment .
• Net cash provided by financing activities: $0 in 2026, compared to $3,252 thousand in 2025 .
• Net decrease in cash, cash equivalents, and restricted cash: - $11,119 thousand in 2026, compared to - $22,415 thousand in 2025 .
• Cash, cash equivalents, and restricted cash at the end of the period: $45,062 thousand in 2026, compared to $36,233 thousand in 2025 .

Unique Metrics

• Accumulated Deficit: As of March 31, 2026, Biomea Fusion, Inc. had an accumulated deficit of $461.5 million .
• Common Stock Outstanding: 72,299,440 shares as of March 31, 2026 .
• Warrant Liability: The fair value of warrant liability was $18,372 thousand as of March 31, 2026 .

Future Outlook and Strategy

Biomea Fusion, Inc. is a clinical-stage company focused on developing novel small molecule therapies for diabetes and obesity . Its lead drug candidate, icovamenib, is currently undergoing two Phase II clinical trials (COVALENT-211 and COVALENT-212) for type 2 diabetes, with topline results from the COVALENT-112 trial in type 1 diabetes reported in April 2026 . The company also anticipates Phase I trial data for BMF-650, a GLP-1 RA for obesity, in the second quarter of 2026 . Biomea Fusion, Inc. plans to seek partnerships for its oncology assets (BMF-500) to focus internal resources on metabolic disorders . The company’s existing cash of $45.1 million as of March 31, 2026, is projected to fund operations only into the first quarter of 2027, necessitating additional capital for future operations .